EPA added to statins reduced coronary plaque measures in a trial review
The review found a plaque-volume signal for EPA, while results for mixed EPA/DHA were inconclusive; the analysis did not measure clinical benefit.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Adding EPA to statins produced greater reductions in total and lipid plaque volumes than statins alone. The mixed EPA/DHA comparison was not statistically significant. These results concern coronary imaging measurements, rather than heart attacks or survival, and differing significance across comparisons does not by itself establish that EPA outperforms the mixture.
The abstract does not report treatment duration, doses, or a direct EPA-versus-mixture effect estimate. Its plaque measurements cannot establish the size or existence of a benefit for clinical cardiovascular events.
What was measured
Researchers combined trials measuring changes in total coronary plaque volume and its lipid component. Both measures favored EPA added to statins in comparisons with statins alone. This answers an imaging question in patients receiving statin therapy.
How to read the mixed result
The EPA/DHA mixture did not show a statistically significant difference from statins alone. That does not prove the treatments are equivalent. A comparative claim about the formulations requires their comparison and uncertainty, beyond separate tests against statins.
The original publication
Effects of purified eicosapentaenoic acid versus mixed eicosapentaenoic/docosahexaenoic acid pharmacotherapies on coronary plaque volume: network meta-analysis of prospective coronary imaging trials.
Sheppard JP, Lakshmanan S, Palatnic L et al.
Acta Cardiol · 2025
- PubMed ID
- 40795199
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.